1. Home
  2. KGEI vs CDXS Comparison

KGEI vs CDXS Comparison

Compare KGEI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kolibri Global Energy Inc. Common stock

KGEI

Kolibri Global Energy Inc. Common stock

HOLD

Current Price

$4.11

Market Cap

163.1M

Sector

N/A

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.82

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGEI
CDXS
Founded
2008
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
163.1M
141.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
KGEI
CDXS
Price
$4.11
$1.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
71.3K
1.5M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
1.99
N/A
EPS
0.49
N/A
Revenue
$60,121,000.00
$52,932,000.00
Revenue This Year
$6.94
$15.64
Revenue Next Year
$14.53
$5.23
P/E Ratio
$8.31
N/A
Revenue Growth
10.00
N/A
52 Week Low
$3.71
$1.52
52 Week High
$9.89
$6.08

Technical Indicators

Market Signals
Indicator
KGEI
CDXS
Relative Strength Index (RSI) 49.79 46.48
Support Level $3.94 $1.62
Resistance Level $4.11 $1.79
Average True Range (ATR) 0.15 0.10
MACD 0.06 0.05
Stochastic Oscillator 89.72 93.44

Price Performance

Historical Comparison
KGEI
CDXS

About KGEI Kolibri Global Energy Inc. Common stock

Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: